|
|
Post by jjacobs122 on Apr 17, 2020 9:43:46 GMT -5
Hopeful Coronavirus News: Doctors Learn More About Treatment is the article on bloomberg.com/ by Faye Flam
Article describes 2 subsets of patients with Coronavirus.
One subset presents with symptoms of high altitude pulmonary edema which is associated with pulmonary arterial hypertension. Article mentioned an inhalable therapy being tried in the subset of patients presenting in this way. My understanding is that the gold standard treatment for pulmonary arterial hypertension is United Therapeutics Treponistil. UT is developing an inhalable from of this drug in partnership with Mankind Corporation and their unique inhaler. Do we know if the drug being tested is the inhalable form of Treponistil?
Article describes Dr. Luciano Gattinoni, an intensive care doctor and guest professor at the University of Gottingen in Germany, in the journal Intensive Care Medicine.
|
|
|
|
Post by louaboardalia on Apr 17, 2020 9:57:48 GMT -5
|
|
|
|
Post by peppy on Apr 17, 2020 9:58:56 GMT -5
Hopeful Coronavirus News: Doctors Learn More About Treatment is the article on bloomberg.com/ by Faye Flam Article describes 2 subsets of patients with Coronavirus. One subset presents with symptoms of high altitude pulmonary edema which is associated with pulmonary arterial hypertension. Article mentioned an inhalable therapy being tried in the subset of patients presenting in this way. My understanding is that the gold standard treatment for pulmonary arterial hypertension is United Therapeutics Treponistil. UT is developing an inhalable from of this drug in partnership with Mankind Corporation and their unique inhaler. Do we know if the drug being tested is the inhalable form of Treponistil? Article describes Dr. Luciano Gattinoni, an intensive care doctor and guest professor at the University of Gottingen in Germany, in the journal Intensive Care Medicine. watching a physician talk about coronavirus, it turns out that with the cytokine storm that happens in ~ 5% of the ER people as it worsens involves pulmonary hypertension. Talafadil the treatment. |
|
|
|
Post by jjacobs122 on Apr 17, 2020 9:59:17 GMT -5
Supporting research abstract in journal Intensive Care Medicine
|
|
|
|
Post by jjacobs122 on Apr 17, 2020 10:03:25 GMT -5
|
|
|
|
Post by Clement on Apr 17, 2020 11:46:13 GMT -5
|
|
|
|
Post by jjacobs122 on Apr 17, 2020 12:00:55 GMT -5
I know the actual study was stopped, but that does not mean it is not being used in Covid patients in dire condition. Does anyone have info on the latter?
|
|
|
|
Post by rfogel on Apr 17, 2020 13:35:01 GMT -5
Off the top of my head, it sounds as though the increase in pulmonary blood pressure is due to the pulmonary edema caused by the virus and/or cytokine storm. The edema -- about 1.5 kg increase in weight per the article -- compresses blood vessels, decreases compliance, increases shunting and makes pushing blood through the lungs more difficult. Eliminating the pulmonary hypertension likely wouldn't help the overall condition. It's the edema that needs to be eliminated.
|
|
|
|
Post by agedhippie on Apr 17, 2020 18:20:20 GMT -5
I know the actual study was stopped, but that does not mean it is not being used in Covid patients in dire condition. Does anyone have info on the latter? It's in the clinical trial filing: The study was stopped because of low recruitment. The limited number of subjects make it difficult to draw conclusions regarding the efficacy of Treprostinil in subjects at high risk of developing ARDS.They only had 14 people, 10 on Treponostil and 4 on the placebo. They needed more people. |
|
|
|
Post by jjacobs122 on Apr 17, 2020 19:01:03 GMT -5
Thanks for the information. The subset they talk about in the article do not fulfill the criteria for ARDS. Unlike ARDS these are people with hypoxemia and near normal compliance of the lungs. Patients have the appearance is more like that of high altitude pulmonary edema in this subset of patients with pulmonary arterial hypertension. That’s why I was wonderingWhether they might be using the unit United therapeutics drug in this subset of patients
|
|
|
|
Post by longliner on Apr 17, 2020 19:39:15 GMT -5
The fact that UTHR has a lung division, grows lungs, treats lung disease and is partnered with Mannkind, suggests, as to defy logic, that they are not pursuing treatment options for covid 19. Martine's daughter has lung ailments (that is how they got into treatment). This additional threat, I'm sure, has not gone unnoticed.
|
|
|
|
Post by jjacobs122 on Apr 18, 2020 9:40:21 GMT -5
I am not talking about patients with pulmonary care of hypertension. I’m talking about the subset of patients with coronavirus who instead of presenting with an ARDS type clinical presentation present with a presentation more similar to high altitude pulmonary edema. One of the characteristics of high altitude pulmonary edema is pulmonary hypertension. My question is whether anyone knows if United therapeutics is currently trying inhaled Treponostil anecdotally on coronavirus patients rather than in a clinical trial. Does anyone have any information on this?
|
|
|
|
Post by brotherm1 on Apr 18, 2020 21:44:06 GMT -5
Looks like United has other plans: NEWS PROVIDED BY Celularity Inc. Apr 09, 2020, 11:00 ET WARREN, N.J., April 9, 2020 /PRNewswire/ -- Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS). This announcement builds on recent pioneering work by Celularity for the use of its proprietary CYNK-001 for the treatment of the SARS-CoV-2 virus that causes the coronavirus disease, COVID-19, and extends this application of the technology to ARDS. The U.S. Food and Drug Administration recently cleared Celularity's investigational new drug application (IND 019650) to evaluate CYNK-001's safety, tolerability, and efficacy for the treatment of COVID-19. www.prnewswire.com/news-releases/celularity-expands-strategic-collaboration-with-united-therapeutics-corporation-to-covid-19-infection-and-acute-respiratory-distress-syndrome-301038319.html |
|
|
|
Post by rfogel on Apr 19, 2020 0:13:25 GMT -5
Looks like United has other plans: NEWS PROVIDED BY Celularity Inc. Apr 09, 2020, 11:00 ET WARREN, N.J., April 9, 2020 /PRNewswire/ -- Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS). This announcement builds on recent pioneering work by Celularity for the use of its proprietary CYNK-001 for the treatment of the SARS-CoV-2 virus that causes the coronavirus disease, COVID-19, and extends this application of the technology to ARDS. The U.S. Food and Drug Administration recently cleared Celularity's investigational new drug application (IND 019650) to evaluate CYNK-001's safety, tolerability, and efficacy for the treatment of COVID-19. www.prnewswire.com/news-releases/celularity-expands-strategic-collaboration-with-united-therapeutics-corporation-to-covid-19-infection-and-acute-respiratory-distress-syndrome-301038319.html"CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy..." There's those natural killer cells popping back up again. |
|
|
|
Post by peppy on Apr 19, 2020 1:22:26 GMT -5
Looks like United has other plans: NEWS PROVIDED BY Celularity Inc. Apr 09, 2020, 11:00 ET WARREN, N.J., April 9, 2020 /PRNewswire/ -- Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS). This announcement builds on recent pioneering work by Celularity for the use of its proprietary CYNK-001 for the treatment of the SARS-CoV-2 virus that causes the coronavirus disease, COVID-19, and extends this application of the technology to ARDS. The U.S. Food and Drug Administration recently cleared Celularity's investigational new drug application (IND 019650) to evaluate CYNK-001's safety, tolerability, and efficacy for the treatment of COVID-19. www.prnewswire.com/news-releases/celularity-expands-strategic-collaboration-with-united-therapeutics-corporation-to-covid-19-infection-and-acute-respiratory-distress-syndrome-301038319.htmlWell, there it is, "from human placentas," |
|
